Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
Portfolio Pulse from
Enlivex Therapeutics Ltd. announced positive interim data from its Phase I/II Allocetra™ trial, showing a 47% reduction in pain for knee osteoarthritis patients after six months.
March 03, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enlivex Therapeutics Ltd. reported positive interim results from its Allocetra™ trial, showing a significant 47% reduction in pain for knee osteoarthritis patients after six months.
The positive interim data from the Allocetra™ trial is likely to boost investor confidence in Enlivex's product pipeline, potentially leading to a short-term increase in stock price. The significant pain reduction in patients is a promising indicator of the treatment's efficacy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100